08:58 AM EST, 11/17/2025 (MT Newswires) -- Merus (MRUS) and Halozyme Therapeutics ( HALO ) agreed to a global non-exclusive collaboration and license agreement, the two companies said on Monday.

Under the collaboration, Merus has licensed Halozyme's Enhanze drug delivery technology for the development and potential commercialization of subcutaneous administration of petosemtamab, the companies said.

Merus will also make an upfront payment to Halozyme and potential future milestone payments related to commercial and sales goals. Halozyme will also be entitled to up to low-mid single digit royalties on net sales of petosemtamab formulated with the Enhanze system, according to a statement.